Only one case report indicated that a patient of NSCLC with a BRAF ex15 p.T599dup mutation exhibited a durable response to the combination therapy of dabrafenib + trametinib (Turshudzhyan and Vredenburgh 2020). This evidence concerns the gene BRAF and non-small cell lung carcinoma.